China Needs To Align With International Standards To Grow Its Biologics Industry: BIO
This article was originally published in PharmAsia News
Executive Summary
On the plus side, China has pledged policy support and hefty funding to build up its biologics industry. However, weak intellectual property protection, a challenging regulatory environment and market access and profitability issues still deter industry investment, according to the Biotechnology Industry Organization.